J9303
J9303 – Injection, panitumumab, 10 mg · NDC Crosswalk & Billing Units
HCPCS Level II J-code · Medicare Part B drug billing
J-code
● 4 NDCs crosswalked per 10 MG $182.189/unit ASP+6%
📋 J9303 summary
J9303 is a HCPCS Level II J-code used to bill panitumumab, 10 mg, billed per 10 MG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.
Brand names associated with J9303: Vectibix
Code J9303
Billing unit 10 MG Payment limit $182.189/unit NDC-Crosswalk 4
Quarter Q3 2026
RxCUI Atlas Trace the drug concept →
⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.
🗂️ Key billing facts
HCPCS codeJ9303
DescriptorInjection, panitumumab, 10 mg
Billing unit10 MG
Payment limit / unit$182.189
Est. ASP / unit$171.876 est.
Mapped NDCs4
Data periodQ3 2026
Last updated2026-08-20
💊 About Panitumumab Injection DRUG GUIDE
Vectibix (panitumumab injection) is used to treat metastatic colorectal cancer (mCRC) in adults.
It is approved for patients whose tumors have a specific genetic profile — either wild-type RAS (no RAS mutations in KRAS or NRAS) or a KRAS G12C mutation — as confirmed by an FDA-approved test before starting treatment.For wild-type RAS mCRC, Vectibix may be used alone after prior chemotherapy has stopped working, or in combination with FOLFOX chemotherapy as a first-line treatment.
For KRAS G12C-mutated mCRC, Vectibix is used in combination with sotorasib in patients who have already received fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
Vectibix is not appropriate for patients with RAS-mutant mCRC (except in the specific KRAS G12C combination setting) or for patients whose RAS mutation status is unknown.
Clinical overview from our editorial drug guide for Panitumumab Injection. For billing reference, see the sections above.
🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026
📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$182.189
Est. ASP / unit
$171.876 est.
Est. after 2% sequester
$178.545
HCPCS dosage
10 MG
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.
Full HCPCS code details (official CMS record)
Long descriptionInjection, panitumumab, 10 mg
CoverageC — Carrier/MAC judgment
Pricing indicator51 — Drug — priced under the ASP methodology
Type of service1 — Medical care
BETOS-2O1D
ASC payment groupYY
Action codeN — No maintenance this year
Effective date2008-01-01
Date added2008-01-01
Source: CMS HCPCS Level II code file (imported via admin).
🧮 Dosing & billing-units calculator HCPCS UNITS
One billing unit of J9303 = 10 mg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.
🔁 NDCs that bill under J9303 WITH EST. MEDICARE PAY
4 NDCs map to J9303. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($182.189/unit) × that package's bill units.
| NDC (11-digit) | Drug | Labeler | Package | Strength | Bill units | Est. pay / pkg | NADAC / unit | Status | Source |
|---|---|---|---|---|---|---|---|---|---|
| 55513-0954-01 | Vectibix panitumumab 100 mg/5mL SOLUTION | Amgen, | 1 VIAL, SINGLE-DOSE in 1 CARTON (55513-954... | 100 mg/5mL | 10 | $1,821.89 | — | ● Active | CMS + PDAC |
| 55513-0954-21 | Vectibix panitumumab 100 mg/5mL SOLUTION | Amgen, | 1 VIAL, SINGLE-DOSE in 1 CARTON (55513-954... | 100 mg/5mL | 10 | $1,821.89 | — | ● Active | CMS + PDAC |
| 55513-0956-01 | Vectibix panitumumab 400 mg/20mL SOLUTION | Amgen, | 1 VIAL, SINGLE-DOSE in 1 CARTON (55513-956... | 400 mg/20mL | 40 | $7,287.56 | — | ● Active | CMS + PDAC |
| 55513-0956-21 | Vectibix panitumumab 400 mg/20mL SOLUTION | Amgen, | 1 VIAL, SINGLE-DOSE in 1 CARTON (55513-956... | 400 mg/20mL | 40 | $7,287.56 | — | ● Active | CMS + PDAC |
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.
📊 Medicare utilization & spend CMS · PART B · 2026 (Q1)
Period
Total Part B spend
$41.65M
Claims
5,053
Beneficiaries
1,562
Spend / beneficiary
$26,665.20
Spend / claim
$8,242.83
Trend by period
Where J9303 ranks among Part B drugs · 2026 (Q1) · neighbors ±5
Total spending — #77 of 824
#72
ERBITUX J9055
$44.95M
#73
ELIGARD* J9217
$43.65M
#74
VYALEV J7356
$43.08M
#75
ABRAXANE* J9264
$42.14M
#76
COMIRNATY * 91320
$42.06M
#77
VECTIBIX J9303
$41.65M
#78
MONOFERRIC J1437
$41.02M
#79
TALVEY J3055
$40.41M
#80
YUPELRI J7677
$40.3M
#81
UDENYCA AUTOINJECTOR... Q5111
$39.49M
#82
PHESGO J9316
$38.43M
Total claims — #223 of 824
#218
ATROPINE SULFATE(J04... J0461
5,212
#219
TECVAYLI J9380
5,187
#220
MULTIHANCE A9577
5,179
#221
TRIVISC J7329
5,171
#222
EVEROLIMUS* J7527
5,068
#223
VECTIBIX J9303
5,053
#224
DACOGEN* J0894
4,978
#225
CUVITRU J1555
4,827
#226
TYSABRI J2323
4,821
#227
DOXIL* Q2050
4,593
#228
AMVUTTRA J0225
4,551
Top Medicare Part B drugs by the selected metric. Click any drug to open its J-code page. Source: CMS Medicare Quarterly Part B Spending by Drug.
Full breakdown by period (2)
| Period | Total spend | Beneficiaries | Claims | $/beneficiary | $/claim |
|---|---|---|---|---|---|
| 2026 (Q1) | $41.65M | 1,562 | 5,053 | $26,665.20 | $8,242.83 |
| 2025 (Q1-Q4) | $160.76M | 2,852 | 19,937 | $56,367.22 | $8,063.37 |
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.
📈 Medicare Part B claims detail CMS PSPS · 2024
Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$52.49M
Medicare paid
$41.66M
Submitted services
327,978
Denial rate
4.8%
Allowed / service
$168.14
Submitted charges
$133.78M
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.
🗺️ Where J9303 is utilized
⏳
The geographic utilization map is building for this code — it aggregates millions of CMS Part B claim lines, then caches the result. Refresh in a moment; if it doesn’t appear, this code may have no reportable Part B utilization.
📊 What bills under J9303
J-codes are billing codes often used for drugs billed under the medical benefit. This connects the billing code to the NDC package records it covers, by ingredient and labeler.
NDC products by ingredient
NDC products by labeler
🗃️ Data sources & freshness
Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Loaded
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-08-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk + DMEPDAC (PDAC)
4 NDCs mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Not available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2026
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.
⚠️ Practical billing caveats
- A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
- Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
- Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
- Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
- The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
- Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.
❓ J9303 billing FAQ
What is HCPCS code J9303?
J9303 is a HCPCS Level II J-code used to bill Injection, panitumumab, 10 mg under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J9303?
One unit of J9303 represents 10 MG. Report the number of units equal to the dose administered divided by 10 MG.
How many units of J9303 should I bill?
Divide the dose administered by the code's unit size (10 MG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J9303?
The Medicare Part B payment limit is $182.189 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $178.545 per unit. Payment limits are revised quarterly.
Which NDCs bill under J9303?
4 NDCs currently map to J9303 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J9303 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.